3,883
edits
Changes
→Role in Cancer
===Role in Cancer===
===Role in Cancer===
''IDH1'' mutations are most common in certain glioma subtypes, having been identified in approximately 80% of WHO grade II and III astrocytomas and oligodendrogliomas, and secondary glioblastomas[20]. In the context of glioma, ''IDH1'' mutations are associated with an improved outcome and a younger age at diagnosis [21,22]. They are, however, rare in patients younger than 18 years.
''IDH1'' mutations are most common in certain glioma subtypes, having been identified in approximately 80% of WHO grade II and III astrocytomas and oligodendrogliomas, and secondary glioblastomas [20]. In the context of glioma, ''IDH1'' mutations are associated with an improved outcome and a younger age at diagnosis [21,22]. They are, however, rare in patients younger than 18 years.
Up to 40% of chondrosarcomas have been observed with IDH1 mutations, where they predict a shorter survival than in patients without ''IDH1'' mutations. There are no clear associations with ''IDH1'' mutation status and histological grade or age at diagnosis in the context of chondrosarcomas [23,24]. ''IDH1'' mutations are not observed in other mesenchymal tumours. One study found somatic ''IDH1'' mutations in a majority (~80%) of enchondromas and spindle cell hemangiomas from patients with Ollier disease and Maffucci syndrome [25].
Up to 40% of chondrosarcomas have been observed with IDH1 mutations, where they predict a shorter survival than in patients without ''IDH1'' mutations. There are no clear associations with ''IDH1'' mutation status and histological grade or age at diagnosis in the context of chondrosarcomas [23,24]. ''IDH1'' mutations are not observed in other mesenchymal tumours. One study found somatic ''IDH1'' mutations in a majority (~80%) of enchondromas and spindle cell hemangiomas from patients with Ollier disease and Maffucci syndrome [25].